Lytgobi Disease Interactions
There are 2 disease interactions with Lytgobi (futibatinib).
Futibatinib (applies to Lytgobi) hepatic impairment
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease
The pharmacokinetics of futibatinib has not been studied in patients with moderate or severe hepatic impairment (total bilirubin greater than 1.5 x ULN and any AST).
References (1)
- (2022) "Product Information. Lytgobi (futibatinib)." Taiho Oncology, Inc., 1
Futibatinib (applies to Lytgobi) renal dysfunction
Moderate Potential Hazard, Moderate plausibility.
The pharmacokinetics of futibatinib has not been studied in patients with severe renal impairment (CrCl 15 to 29 mL/min), renal dialysis in end-stage renal disease (CrCl less than 15 mL/min).
References (1)
- (2022) "Product Information. Lytgobi (futibatinib)." Taiho Oncology, Inc., 1
Switch to consumer interaction data
Lytgobi drug interactions
There are 179 drug interactions with Lytgobi (futibatinib).
Lytgobi alcohol/food interactions
There is 1 alcohol/food interaction with Lytgobi (futibatinib).
More about Lytgobi (futibatinib)
- Lytgobi consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.